Top Radiation Oncology Expert LAN Shengmin Joins Our Hospital
Renowned Oncology Expert Joins Our Hospital
Dr. Lan Shengmin, Leading Radiation Oncologist from Shanxi, Strengthens Our Medical Team
On June 14, Professor Lan Shengmin, Chairman of the Radiation Oncology Committee of the Shanxi Medical Association and Deputy Director of the Head and Neck Cancer Committee of the Shanxi Branch of the Chinese Anti-Cancer Association, officially joined the Wuwei Heavy Ion Center. He conducted a series of important academic exchange activities, including clinical rounds in various radiotherapy departments, participation in discussions on complex cases, and providing guidance on cutting-edge technologies.
Professor Lan Shengmin is a senior expert in radiation oncology, holding the titles of Chief Physician and Master’s Supervisor. He has served in key leadership roles, including Committee Member of the Radiation Oncology Branch of the Chinese Medical Association, Committee Member of the Radiation Oncology Branch of the Chinese Anti-Cancer Association, and Director of the Radiation Oncology Committee of the Shanxi Medical Association. He has been awarded three Provincial Science and Technology Progress Awards (Second Class).
With over 20 years of experience in tumor radiotherapy, Professor Lan specializes in the diagnosis, treatment, and prognostic analysis of head and neck tumors, neurologic tumors, bone and soft tissue tumors, skin tumors, breast cancer, malignant lymphoma, as well as intracranial and cervical metastases of esophageal and lung cancers. He possesses unique insights and extensive clinical expertise in radiation oncology, hyperthermia, chemotherapy, and biological therapy, earning him high recognition and broad influence within the medical community.
Professor Lan Shengmin’s appointment marks a significant achievement for Wuwei Cancer Hospital in Gansu Province, advancing its initiatives in the Heavy Ion Therapy Alliance and the establishment of 50 expert workstations.
As the world’s only hospital operating two heavy ion therapy systems simultaneously, Wuwei Cancer Hospital remains committed to the continuous development and innovation of tumor treatment technologies. Since the official clinical operation of the Wuwei Heavy Ion Center in March 2020, the hospital has successfully treated over 2,000 patients, achieving remarkable clinical outcomes.
The center treats a wide range of cancers, including lung cancer, pancreatic cancer, liver cancer, glioblastoma, and more than 50 other malignancies. Patients come from all provinces and municipalities across China, as well as Hong Kong, Macau, and Taiwan, along with international cases from Australia, Belgium, South Korea, Malaysia, and other countries.
During his ward rounds, Professor Lan Shengmin conducted thorough examinations of each patient's condition and treatment progress. He engaged in in-depth discussions with radiation oncology specialists, analyzing cases from multiple perspectives. Based on individual patient assessments, he proposed precise and personalized treatment recommendations. Professor LAN particularly emphasized that cancer treatment is a comprehensive and complex process that requires full consideration of various factors-including the patient's overall health status, tumor type, and disease stage-to develop the most appropriate and individualized therapeutic plan.
The addition of Professor Lan Shengmin will undoubtedly significantly enhance the academic development and clinical capabilities of the Wuwei Heavy Ion Center. Looking ahead, Wuwei Cancer Hospital in Gansu Province remains committed to advancing the Heavy Ion Therapy Alliance and expanding its network of 50 expert workstations, continuously strengthening its comprehensive strengths.
We firmly believe that under the leadership of distinguished experts including Professor Lan Shengmin, Zhang Yingdong, Ma Changying, and Fan Ruitai, the Wuwei Heavy Ion Center will achieve even greater accomplishments in the field of cancer treatment, bringing new hope and light to countless patients suffering from malignancies.